BeStock  
Stocks › Biotechnology › PVLA

Palvella Therapeutics PVLA

US equityMarket cap rank #2653Biotechnology
$142.85 −$2.92 (-2.00%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $142.85 0.00%
Open$143.10
Prev close$145.77
Day range$142.22 – $148.69
Volume192.7K
Market cap$2.09B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$22.73M-123.3% YoY
Net profit-$24.64M-117.2% YoY
Diluted EPS-$1.70-65.0% YoY
Free cash flow-$14.43M-83.1% YoY
Operating cash flow-$14.43M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-4.0MDec '24$-8.2MMar '25$-9.5MJun '25$-11.3MSep '25$-12.7MDec '25$-15.8MMar '26$-21.9MJun '26$-24.6MSep '26

Diluted EPS by quarter

-0.31Dec '24-0.74Mar '25-0.86Jun '25-1.03Sep '25-1.08Dec '25-1.20Mar '26-1.52Jun '26-1.70Sep '26

Free cash flow by quarter

$-5.4MDec '24$-6.8MMar '25$-5.4MJun '25$-7.9MSep '25$-4.9MDec '25$-10.9MMar '26$-12.8MJun '26$-14.4MSep '26

Annual revenue

$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-63.4%
Return on assets-49.0%
Return on invested capital-60.8%
Current ratio16.01
Liabilities / assets17.3%
Cash & investments$236.68M
Total debt$260,000.00
Net cash (debt)$236.42M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $22.73M $21.41M $14.86M $38.60M $11.30M
Selling and Admin Expenses $11.90M $8.93M $5.52M $15.76M $4.18M
-General & Admin Expense $11.90M $8.93M $5.52M $15.76M $4.18M
Research & Development $10.82M $12.47M $9.33M $22.84M $7.12M
Operating Profit -$22.73M -$21.41M -$14.86M -$38.60M -$11.30M
Net Non-Operating Interest Income (Expense) -$263,000.00 -$343,000.00 -$966,000.00 -$3.23M -$1.22M
Non-Operating Interest Income $2.55M $1.97M $1.07M $2.59M $520,000.00
Non-Operating Interest Expense $2.81M $2.31M $2.04M $5.82M $1.74M
Other Income (Expense) -$1.65M -$122,000.00 $54,000.00 $115,000.00 -$191,000.00
Gain on Sale of Security -$1.65M -$114,000.00 $86,000.00 -$612,000.00 -$99,000.00
Other Non-Operating Income (Expenses) -$6,000.00 -$8,000.00 -$32,000.00 $727,000.00 -$92,000.00
Pretax Profit -$24.64M -$21.87M -$15.77M -$41.72M -$12.71M
Tax $0.00 $0.00 $0.00 $0.00 $0.00
Net Profit -$24.64M -$21.87M -$15.77M -$41.72M -$12.71M
Profit from Continuing Operations -$24.64M -$21.87M -$15.77M -$41.72M -$12.71M
Net Income to Parent Company -$24.64M -$21.87M -$15.77M -$41.72M -$12.71M
Net Income to Common Stockholders -$24.64M -$21.87M -$15.77M -$41.72M -$12.71M
Basic EPS -$1.70 -$1.52 -$1.20 -$3.71 -$1.08
Diluted EPS -$1.70 -$1.52 -$1.20 -$3.71 -$1.08

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $239.40M $253.51M $263.76M $59.56M $59.56M
Total Current Assets $238.97M $253.03M $263.23M $58.99M $58.99M
Cash and Cash Equivalents & Short-Term Investments $236.68M $250.58M $261.85M $57.98M $57.98M
-Cash and Cash Equivalents $193.30M $187.80M $206.39M $57.98M $57.98M
-Short Term Investments $43.38M $62.78M $55.46M – –
Other Current Assets $2.29M $2.44M $1.38M $1.01M $1.01M
Total Non-Current Assets $435,000.00 $482,000.00 $528,000.00 $572,000.00 $572,000.00
Net PPE $435,000.00 $482,000.00 $528,000.00 $572,000.00 $572,000.00
-Gross PPE $435,000.00 $482,000.00 $528,000.00 $572,000.00 $572,000.00
Total Liabilities $41.48M $36.64M $31.45M $31.58M $31.58M
Total Current Liabilities $14.93M $11.95M $9.12M $11.34M $11.34M
Payables $5.16M $6.79M $5.44M $4.60M $4.60M
-Accounts Payable $5.16M $6.79M $5.44M $4.60M $4.60M
Current Accrued Expenses $2.61M $2.23M $1.83M $1.73M $1.73M
Short-Term Debt and Capital Lease Obligation $225,000.00 $217,000.00 $209,000.00 $202,000.00 $202,000.00
-Current Capital Lease Obligation $225,000.00 $217,000.00 $209,000.00 $202,000.00 $202,000.00
Other Current Liabilities $3.89M $1.24M $960,000.00 $2.90M $2.90M
Total Non-Current Liabilities $26.55M $24.70M $22.33M $20.23M $20.23M
Long Term Debt and Capital Lease Obligation $260,000.00 $318,000.00 $375,000.00 $431,000.00 $431,000.00
-Long Term Capital Lease Obligation $260,000.00 $318,000.00 $375,000.00 $431,000.00 $431,000.00
Derivative Product Liabilities $1.37M $2.27M $2.16M $2.04M $2.04M
Other Non-Current Liabilities $24.92M $22.11M $19.80M $17.76M $17.76M
Total Equity $197.92M $216.87M $232.31M $27.98M $27.98M
Stockholders' Equity $197.92M $216.87M $232.31M $27.98M $27.98M
Capital Stock $15,000.00 $14,000.00 $14,000.00 $12,000.00 $12,000.00
-Common Stock $15,000.00 $14,000.00 $14,000.00 $12,000.00 $12,000.00
Additional Paid-In Capital $395.58M $389.85M $383.42M $163.34M $163.34M
Retained Earnings -$197.73M -$173.09M -$151.22M -$135.45M -$135.45M
Gains/Losses Not Affecting Retained Earnings $56,000.00 $89,000.00 $95,000.00 $83,000.00 $83,000.00
Receivables – – – $0.00 $0.00
-Accounts Receivable – – – $0.00 $0.00
-Taxes Receivable – – – $0.00 $0.00
-Preferred Stock – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$14.43M -$12.85M -$10.86M -$25.01M -$4.93M
Net cash flow from continuing operations -$14.43M -$12.85M -$10.86M -$25.01M -$4.93M
Net Income from Continuing Operations -$24.64M -$21.87M -$15.77M -$41.72M -$12.71M
Gain/Loss from Continuing Operations $1.12M $114,000.00 -$86,000.00 $612,000.00 $99,000.00
Other Non-Cash Items $3.15M $1.98M $2.02M $5.88M $1.80M
Change in Working Capital $529,000.00 $1.77M -$406,000.00 $3.82M $3.80M
-Change in Prepaid Assets $195,000.00 -$1.07M -$357,000.00 $1.36M $222,000.00
-Change in Payables and Accrued Expense $334,000.00 $2.84M -$49,000.00 -$40,000.00 $1.45M
Net cash flow from investing $19.57M -$7.03M -$55.44M – –
Net Cash Flow from Continuing Investing Activities $19.57M -$7.03M -$55.44M – –
Net Investment Purchase and Sale $19.57M -$7.03M -$55.44M – –
Financing Cash Flow $452,000.00 $1.28M $214.73M -$660,000.00 -$49,000.00
Net Cash Flow from Continuing Financing Activities $452,000.00 $1.28M $214.73M -$660,000.00 -$49,000.00
Net Common Stock Issuance $0.00 $0.00 $230.00M – –
Proceeds from Stock Option Exercised $452,000.00 $1.28M $956,000.00 $763,000.00 $105,000.00
Net Other Financing Charges $0.00 $0.00 -$16.23M -$1.42M -$154,000.00
Ending Cash Balance $193.30M $187.80M $206.39M $57.98M $57.98M
Net Change in Cash $5.60M -$18.60M $148.43M -$25.67M -$4.98M
Beginning Cash Balance $187.80M $206.39M $57.98M $83.60M $63.57M
Effect of Exchange Rate Changes -$102,000.00 $6,000.00 -$15,000.00 $46,000.00 -$610,000.00
Free Cash Flow -$14.43M -$12.85M -$10.86M -$25.01M -$4.93M
-Change in Receivables – – – $2.49M $2.13M
Net Issuance Payments Of Debt – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on PVLA.

Sign in to join the discussion.

Scroll to Top